Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Duchemann

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
La Revue Du Praticien|June 23, 2021
["Prescription and monitoring of the most common classes of drugs in adults and children, excluding anti-infectives (see item 177). Know the correct use of the main therapeutic classes"]Laurent Zelek, Boris Duchemann
Bulletin Du Cancer|October 2, 2024
[Nivolumab plus chemotherapy in neoadjuvant treatment of NSCLC with PD-L1 expression≥1]Romuald Crenier, Boris Duchemann
Bulletin Du Cancer|October 27, 2021
[Drug approval: Osimertinib as an adjuvant treatment of non-small cell lung carcinoma with EFGR mutation after complete resection]Diane Chevassut, Boris Duchemann
La Revue Du Praticien|March 8, 2022
[Cancer treatments]Laurent Zelek, Boris Duchemann
Blood|November 25, 2021
Post-SARS-CoV-2 vaccination acute hemolysis in an older man: don't forget to look at the blood smearBoris Duchemann, Gregory Lazarian
La Revue Du Praticien|December 5, 2018
Cancer treatment. Surgery, radiotherapy, medical treatments (chemotherapy, targeted therapies, immunotherapy). Multidisciplinary therapeutic decision and patient informationBoris Duchemann, Laurent Zelek
The European Respiratory Journal|May 2, 2015
Therapeutic management of ALK+ nonsmall cell lung cancer patientsBoris Duchemann, Luc Friboulet, Benjamin Besse
Translational Lung Cancer Research|December 10, 2025
Perioperative chemo immunotherapy in non-small-cell lung cancer: what can we learn from the long-term results of NADIM?Xavier Fremand, Ilaria Onorati, Boris Duchemann
Translational Lung Cancer Research|May 13, 2024
The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinibBoris Duchemann, Emmanuelle Fabre, Jordi Remon
Intensive Care Medicine|March 27, 2019
Spectacular improvement of lung computer tomography after treatment with EGFR tyrosine kinase inhibitor for miliary carcinomatosisGabrielle Archer, Boris Duchemann, Stephane Gaudry, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
La Revue Du Praticien|June 23, 2021
["Prescription and monitoring of the most common classes of drugs in adults and children, excluding anti-infectives (see item 177). Know the correct use of the main therapeutic classes"]Laurent Zelek, Boris Duchemann
Bulletin Du Cancer|October 2, 2024
[Nivolumab plus chemotherapy in neoadjuvant treatment of NSCLC with PD-L1 expression≥1]Romuald Crenier, Boris Duchemann
Bulletin Du Cancer|October 27, 2021
[Drug approval: Osimertinib as an adjuvant treatment of non-small cell lung carcinoma with EFGR mutation after complete resection]Diane Chevassut, Boris Duchemann
La Revue Du Praticien|March 8, 2022
[Cancer treatments]Laurent Zelek, Boris Duchemann
Blood|November 25, 2021
Post-SARS-CoV-2 vaccination acute hemolysis in an older man: don't forget to look at the blood smearBoris Duchemann, Gregory Lazarian
La Revue Du Praticien|December 5, 2018
Cancer treatment. Surgery, radiotherapy, medical treatments (chemotherapy, targeted therapies, immunotherapy). Multidisciplinary therapeutic decision and patient informationBoris Duchemann, Laurent Zelek
The European Respiratory Journal|May 2, 2015
Therapeutic management of ALK+ nonsmall cell lung cancer patientsBoris Duchemann, Luc Friboulet, Benjamin Besse
Translational Lung Cancer Research|December 10, 2025
Perioperative chemo immunotherapy in non-small-cell lung cancer: what can we learn from the long-term results of NADIM?Xavier Fremand, Ilaria Onorati, Boris Duchemann
Translational Lung Cancer Research|May 13, 2024
The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinibBoris Duchemann, Emmanuelle Fabre, Jordi Remon
Intensive Care Medicine|March 27, 2019
Spectacular improvement of lung computer tomography after treatment with EGFR tyrosine kinase inhibitor for miliary carcinomatosisGabrielle Archer, Boris Duchemann, Stephane Gaudry, et al.
Pageof 9